Rebiotix

Rebiotix was a clinical-stage biotechnology company focused on developing microbiome-based therapeutics. The company aimed to leverage the complex ecosystem of bacteria, fungi, and viruses that reside in the human gut to treat a variety of diseases. Their primary focus was on developing treatments for conditions such as Clostridioides difficile infection (CDI) and inflammatory bowel disease (IBD).

The core of Rebiotix's approach involved using fecal microbiota transplantation (FMT) to restore a healthy gut microbiome. They developed a proprietary platform called Microbiome Restoration Therapy (MRT) which aimed to standardize and improve the safety and efficacy of FMT. Their lead product candidate, RBX2660, was a standardized FMT delivered via enema, designed to prevent the recurrence of CDI.

Rebiotix conducted clinical trials for RBX2660, showing promising results in reducing CDI recurrence. The company also explored applications of its MRT platform for other gastrointestinal disorders. In 2018, Rebiotix was acquired by Ferring Pharmaceuticals, a global pharmaceutical company. This acquisition aimed to accelerate the development and commercialization of microbiome-based therapies, integrating Rebiotix's technology into Ferring's broader pipeline. The legacy of Rebiotix continues through Ferring's ongoing research and development in the field of microbiome therapeutics.